Search Results
Your search for The ASCO matches 22646 pages
Showing 1 - 50Presidential Symposium Highlights in Small Cell Lung Cancer
Three phase III studies in small cell lung cancer (SCLC) were among the notable findings presented during a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer held in Seoul. The studies addressed important questions...
Real-World Data Are Not Necessarily Real-World Evidence
Real-world data (RWD) provide raw material from which real-world evidence (RWE) is generated, but the two terms are not synonymous. Over the past decade, RWD and RWE have become increasingly prominent in oncology. A search of the 2016 ASCO Annual Meeting abstracts identified 48 with terms “real...
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
On October 16, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high...
Of Note in the Oncology Community: September/October 2026
Areej R. El-Jawahri, MD, FASCO, was named by ASCO as the 2026 recipient of the Joseph Simone Quality Care Award. She accepted her award and presented her keynote lecture at the 2026 ASCO Quality Care Symposium held recently in Boston. Dr. El-Jawahri is Co-Director of the Cancer Outcomes Research...
Three Decades of AYA Cancer Survivorship
Growing up, I was a curious, empathetic kid with an interest in biology. When I was diagnosed with non-Hodgkin lymphoma 2 months before I turned 15, those qualities shaped how I engaged with my care. I asked questions, wanted to understand what was happening in my body, and built strong...
Robert A. Kyle, MD, Renowned Expert in Myeloma, Dies at 98
The International Myeloma Foundation (IMF) shared news on the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly-revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
The final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome were recently presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany...
Mammography Screening for Recurrence After a Diagnosis of Breast Cancer
Nahleh and colleagues recently updated ASCO guidelines regarding the frequency of breast screening following a diagnosis of primary breast cancer and recommended annual mammography for most patients.1 Presumably, the benefit of mammography will come from finding recurrences earlier, e.g., smaller...
Patient-Friendly Research Summaries Spotlight Advances in Pancreatic Cancer
The science and practice of translation is about more than moving discoveries from the lab to the clinic. It also helps break down barriers to access so crucial developments in cancer care can reach patients and improve outcomes all over the world. To help you spread the word about these...
ASCO Issues Its First Living Guideline on Systemic Treatment of Recurrent Ovarian Cancer
In June 2026, an ASCO Expert Panel voted to approve ASCO’s first Living Guideline on systemic treatment of ovarian cancer recurrence.1 The continuously updated, evidence-based guideline addresses patients with epithelial ovarian cancer, primary peritoneal carcinoma, and fallopian tube carcinoma,...
Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials
A recent study by researchers from The Univetsity of Texas MD Anderson Cancer Center, ASCO, and collaborating institutions evaluated the national landscape of geographic access to active triple-negative breast cancer clinical trials. The findings—published by Amin et al in Breast Cancer Research...
Data From Pivotal Trials Lead to Recent Drug Approvals in Colorectal, Breast, RCC, and CLL/SLL Malignancies
In September and October, the U.S. Food and Drug Administration (FDA) released statements regarding the Agency’s approval of a number of oncology drug products across several solid tumors and hematologic malignancies. A summary of these approvals is provided here. Combination Approved in dMMR Colon ...
Remote Expert Case Reviews Identify Opportunities to Improve Cancer Care and Reduce Costs
Remote expert review of oncology cases may help to address and improve gaps in evidence-based cancer care, while also providing measurable cost savings, according to findings presented in a poster at the 2026 ASCO Quality Care Symposium (Abstract 700). “Last year at ASCO's Quality Care Symposium,...
Bivalent CAR T-Cell Therapy Shows Shows Durable Activity and Manageable Safety in Recurrent Glioblastoma
Longer follow-up from a phase I trial of intracerebroventricular bivalent CAR T-cell therapy in recurrent glioblastoma showed no long-term or delayed-onset toxicities, with a median overall survival of 12.0 months, according to updated data presented at the 2026 ASCO Annual Meeting.1 The...
AI Model Based on Facial Image Analysis Estimates Biological Age and Mortality Risk in Patients With Cancer
Analyzing facial images using a foundational artificial intelligence (AI) model may help researchers determine both biological aging and disease-related mortality risk, according to study findings published in The Lancet Digital Health. “As the population ages, physicians need better ways to...
Community Oncology Practices Bring Advances in Cancer Testing and Treatment Closer to Patients
Community oncology practices are bringing personalized medicine into everyday cancer care, substantially expanding their use of advanced biomarker testing and novel therapies for patients with metastatic breast cancer and metastatic non–small cell lung cancer, according to new research from...
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) for the treatment of adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair...
Mocertatug Rezetecan Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
First results from the global phase I BEHOLD-1 study suggest that the investigational B7-H4–targeted antibody-drug conjugate mocertatug rezetecan showed activity in two difficult-to-treat gynecologic cancers: platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.1 At the...
ASH Issues New Recommendations for the Management of Myelofibrosis
The American Society of Hematology (ASH) released new guidelines on the management of myelofibrosis which recommend expanded molecular testing, early transplant referral, appropriate use of JAK inhibitors, and aspirin therapy in select patients. The guidelines were published by Stein et al in Blood ...
Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families, Study Finds
New research published by Rodwin et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that families of children receiving treatment for B-cell acute lymphoblastic leukemia (ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a...
ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is ...
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Survival and mortality disparities for women with breast cancer are widening between rural and urban areas over time, according to findings from two American Cancer Society studies presented at the 2026 ASCO Quality Care Symposium (Abstracts 208 and 253). The studies found that women from rural...
Amyloidosis: Novel Treatments Could Improve Poor Outcomes
Systemic light chain amyloidosis is a clonal plasma cell disorder that can lead to end-organ dysfunction, with no approved treatment in the relapsed/refractory setting. Given this challenging clinical situation, two studies of novel therapies for this disease reported at the 2026 ASCO Annual...
ASCO and WHO Formalize Partnership
Cancer is one of the leading causes of morbidity and mortality worldwide, affecting 92% of families around the world, according to the latest estimates from the World Health Organization (WHO) Global status report on cancer 2026. The highest health, social, and economic burdens occur in low- and...
Study Supports Universal Germline Genetic Testing Regardless of Age at Cancer Diagnosis
Universal germline genetic testing after an individual receives a cancer diagnosis may help to uncover hereditary cancer risks in the patient's family, according to findings published in Cancer Discovery. In a study of a pan–solid tumor cohort, researchers found enriched germline pathogenic...
FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC
On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This...
Automated vs Handheld Ultrasound for Breast Cancer Screening
A new study by Rauscher et al in the Journal of the American College of Radiology has found that automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) had similar cancer detection rates in women with dense breasts, whereas ABUS had a lower false-positive rate. These data demonstrate...
ASCO Remembers Dr. Rachna T. Shroff, Expert in Gastrointestinal Cancers and Dedicated ASCO Volunteer
ASCO joins the oncology community in mourning the death of Rachna T. Shroff, MD, MS, FASCO, a renowned expert specializing in gastrointestinal (GI) cancers and a dedicated ASCO volunteer. Dr. Shroff passed away following a battle with an aggressive cancer. After completing her training, Dr....
Implementing Massage and Acupuncture to Achieve Better Pain Management in Oncology Care: An Overview of the IMAGINE Project
Pain is an incredibly challenging symptom that affects over 40% of patients with cancer in active treatment1 and up to two in three patients with advanced cancer.2 Analgesic pain medications including opioids have been the predominant pain management strategy; however, their use is limited by...
Remote Exercise Program Reduces Cancer-Related Fatigue, Improves Quality of Life for Patients Undergoing Immunotherapy
A supervised remote exercise program improved the quality of life of patients with cancer undergoing immunotherapy, primarily by reducing cancer fatigue, according to findings from a secondary analysis of a phase II trial that will be presented at the 2026 ASCO Quality Care Symposium (Abstract...
Financial Navigation Support May Help Reduce Financial Toxicity for Some People With Advanced Cancer
Results from the randomized nationwide CREDIT trial showed that a financial navigation support program does not broadly reduce financial hardship for people being treated for advanced cancer. However, it can help a subgroup of people: those with existing financial and social resources that make...
The Wistar Institute Names New President and Chief Executive Officer
The Wistar Institute’s Board of Trustees has appointed Ronny Drapkin, MD, PhD, a physician-scientist and ovarian cancer researcher at the University of Pennsylvania Perelman School of Medicine, to be the Institute’s next President and Chief Executive Officer, effective November 30, 2026. Dr....
Early Research Links Abdominal Obesity to Increased Lung Cancer Risk
Findings from a recent study published in the Journal of Thoracic Oncology challenge the idea that an obesity paradox contributes to reduced lung cancer risk—instead, the data suggested that obesity may be associated with enhanced lung carcinogenesis. “Overall, our data clearly associate central ...
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
On October 8, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with stage III mismatch repair–deficient (dMMR) colon cancer. The FDA...
ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic Population
The cancer distribution in the Hispanic population is distinct from the general population in the United States, according to a statistics report from the American Cancer Society (ACS) published in CA: A Cancer Journal for Clinicians. The report indicated fewer lung and urinary bladder cancers,...
Charles M. Perou, PhD, Honored With 2026 William L. McGuire Memorial Lecture Award
Charles M. Perou, PhD, will receive the William L. McGuire Memorial Lecture Award during the San Antonio Breast Cancer Symposium 2026 (SABCS), to be held December 8 to 11 at the Henry B. González Convention Center in San Antonio, Texas. He will present his award lecture, titled “Quantitative...
HER2-Positive Breast Cancer: FDA Approves Triplet for Maintenance Therapy
On October 7, the U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa), a HER2-targeted tyrosine kinase inhibitor, in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast...
GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease
Use of GLP-1 receptor agonist was significantly associated with a lower 5-year incidence of colorectal cancer among patients with inflammatory bowel disease (IBD), including those with concomitant type 2 diabetes, according to findings presented at the 2026 ASCO Breakthrough Meeting in Singapore.1...
Pediatric Bone Sarcoma Gets First NCCN Guidelines
The National Comprehensive Cancer Network (NCCN) has released its first-ever NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for pediatric bone sarcomas. These new guidelines offer a comprehensive set of treatment recommendations for a challenging pediatric cancer, and offer...
2026 Albany Prize Awardees Announced
Tony Hunter, PhD, and Dennis J. Slamon, MD, PhD, have been awarded the 2026 Albany Medical Center Prize in Medicine and Biomedical Research. The two distinguished recipients are being recognized for their breakthrough discoveries that have revolutionized our understanding of the molecular...
Pediatric and Adolescent Colorectal Carcinoma: A Retrospective Analysis
Rates of advanced-stage colorectal cancer are climbing in young patients, marking a need for increased vigilance, according to data presented during the American Academy of Pediatrics 2026 National Conference & Exhibition (Abstract 02-204). Investigators retrospectively examined the medical...
Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study
Autonomous artificial intelligence (AI) as a medical device could be used to address rising dermatology service needs, freeing up clinical capacity to provide about 8,500 more dermatology appointments within 16 months, according to findings from a real-world U.K. study presented at the European...
ER-Positive, HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer experienced significantly improved progression-free survival when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD),...
FDA Approves First-Line Pirtobrutinib for CLL/SLL
On October 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. Efficacy and Safety Efficacy was evaluated in the randomized,...
Lung Cancer: AI Model May Predict Pneumonitis Risk From Immunotherapy
A deep learning foundation model was able to predict pneumonitis risk from immune checkpoint inhibition therapy in patients with non–small cell lung cancer (NSCLC) based on baseline computed tomography (CT) scans, according to findings published in the Journal for ImmunoTherapy of Cancer....
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Cancer death rates fell for both men and women from 2019 to 2023, continuing a downward trend that has lasted more than 20 years, according to the 2026 Annual Report to the Nation on the Status of Cancer, published by Henley et al in the journal Cancer. The continued decline in cancer deaths is...
IARC Panel Provides International Determination on Lung Cancer Screening's Benefits and Harms
The International Agency for Research on Cancer (IARC) has published a comprehensive international evaluation on lung cancer screening in The New England Journal of Medicine. Screening has emerged as a complementary approach to tobacco control and other methods for preventing lung cancer to reduce...
Can Long Distance Running Be a Risk Factor for Early-Onset Colorectal Cancer?
Colorectal cancer, once thought of as mainly a disease of the aging, is rising in younger adults by nearly 3% per year and is now a leading cause of cancer-related death among individuals under the age of 50.1 According to the American Cancer Society, in 2026, nearly 159,000 individuals will be...
FDA Launches Effort to Expand Scientific Expertise, Consumer Voice to Advisory Committees
The U.S. Food and Drug Administration (FDA) recently announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees. The FDA is publishing two Federal Register notices: one seeking qualified scientific, technical, and...
Cleveland Clinic London Appoints Oncology Vice Chief
Cleveland Clinic London has appointed Heather Shaw, MD, FRCP, as Oncology Vice Chief, reinforcing the organization’s commitment to expanding access to advanced, multidisciplinary cancer care in the United Kingdom. Dr. Shaw will lead oncology strategy and service development across Cleveland Clinic...
